Unconfigured Ad

Collapse
X
 
  • Time
  • Show
Clear All
new posts
  • Genohub
    Registered Vendor
    • Mar 2013
    • 210

    #1

    Sfaf 2013

    Day 1 highlights of Sequencing, Finishing and Analysis in the Future Meeting (SFAF 2013)

    • All four platforms are actively trying to increase their read lengths (although we didn’t see significant guidance beyond Ion’s 400 bp reads)
    • Haley mentioned that Illumina’s latest aquisition of Moleculo technology might one day replace current Mate-pair library prep (if prices can be lowered).
    • MiSeq DX was pulled back because Illumina has been able to increase MiSeq output. A clinical instrument will require a locked down platform.
    • Turner said that he expects 30,000 PacBio base pairs in 3 years. Shearing technologies and polymerases would have to be improved for better-read lengths.
    • PGM can produce >2G aligned Q20 bases with even coverage (E. coli) using their 318, 400 bp chip.
    • Fiske said that Illumina spends 25% of revenue on R&D, Life Tech and Thermo spend 5% and 3% respectively.
    • Illumina needs help with better and higher fidelity polymerases. Suggested that Illumina would consider purchasing companies who have breakthrough technologies related to polymerases.

    SFAF day 1 summary
    Last edited by Genohub; 07-29-2013, 02:16 PM. Reason: link update

Latest Articles

Collapse

  • SEQadmin2
    16S/ITS Profiling vs. Shotgun Metagenomics: What Changes in Your Workflow?
    by SEQadmin2




    NGS has revolutionized clinical microbiology by offering new ways to identify and surveil pathogens without prior knowledge of the target. One popular approach is 16S rRNA and ITS amplicon sequencing, which targets specific microbial markers. But studies are increasingly incorporating shotgun metagenomics, a technique that sequences all DNA from a sample without targeting specific microbial markers. This approach allows more detailed taxonomic classification, detection...
    Today, 06:46 AM
  • SEQadmin2
    Multiomic Liquid Biopsy: What DNA/RNA Panels Reveal That DNA Alone Can’t
    by SEQadmin2



    Tumors contain complex mixtures of cell populations that evolve in response to treatment and host-specific factors. Tissue biopsies provide only static snapshots of a tumor’s state. But what if we could follow that evolution over time using a minimally invasive technique?

    Liquid biopsies can detect tumor-derived material circulating in the bloodstream, providing a way to study treatment response, detect emerging resistance, and discover new biomarkers. Circulating
    ...
    10-14-2026, 09:55 AM

ad_right_rmr

Collapse

News

Collapse

Topics Statistics Last Post
Started by SEQadmin2, 10-28-2026, 09:57 AM
0 responses
22 views
0 reactions
Last Post SEQadmin2  
Started by SEQadmin2, 10-28-2026, 09:51 AM
0 responses
14 views
0 reactions
Last Post SEQadmin2  
Started by SEQadmin2, 10-22-2026, 11:13 AM
0 responses
67 views
0 reactions
Last Post SEQadmin2  
Started by SEQadmin2, 10-22-2026, 10:48 AM
0 responses
47 views
0 reactions
Last Post SEQadmin2  
Working...